- •This is the first cost-effectiveness analysis (CEA) of venetoclax in combination with obinutuzumab (VenO) making available the full economic model following Open Science Practices to promote research transparency and reproducibility.
- •This is the first European CEA of VenO considering an extended societal view in scenario analyses including future non-medical costs and possible drug price changes upon their patent expiry.
- •VenO for adult, treatment-naïve CLL patients is cost-effective when compared to ClbO from a Dutch (extended) societal perspective, and this finding may be used to support decision-making in both clinical applications and reimbursement of VenO.
Publication stageIn Press Accepted Manuscript
Author contribution statement
Concept and design : Do, Thielen
Analysis and interpretation of data : Do, Thielen
Drafting of the manuscript : Do
Critical revision of the paper for important intellectual content: Thielen
Statistical analysis : Do
Administrative, technical, or logistic support: Thielen
Supervision : Thielen
Conflict of interest disclosures
Dr Thielen reported previous consultation for AstraZeneca, Optimax Access, Dark Peak Analytics, and reported receiving grants from Celgene outside the submitted work. Previous and ongoing research was or is partly funded by the CADTH (Canadian Agency for Drugs and Technologies in Health), the Dutch Ministry of Health, Welfare and Sport, and the European Haematology Association. No other disclosures were reported.
statements: Not applicable. The authors received no financial support for this research.
Role of funder/sponsor: Not applicable.
Précis: Venetoclax plus obinutuzumab treatment is less costly and more effective than the standard treatment - chlorambucil plus obinutuzumab - to treat treatment-naïve chronic lymphocytic leukemia adult patients.
Acknowledgements: Not applicable
User LicenseCreative Commons Attribution (CC BY 4.0) |
- Read, print & download
- Redistribute or republish the final article
- Text & data mine
- Translate the article
- Reuse portions or extracts from the article in other works
- Sell or re-use for commercial purposes
Elsevier's open access license policy